Download FREE Sample
Report Overview
Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive.
To learn more about this report, download the PDF brochure
Global cancer burden and the rising shift toward multi cancer early detection
The primary factor driving this market is the simple fact that cancer is still one of the leading causes of mortality around the world. According to an article published by the WHO, there were around 20 million new cases of cancer and 9.7 million deaths from cancer in the year 2022. The burden is expected to increase by 77% by 2050, and will further put more pressure on healthcare systems. The rising awareness about early detection of cancer and the surge in the number of cancer cases globally have spurred a major shift in screening methods. Instead of waiting for symptoms or relying on invasive, one cancer at a time tests, many healthcare providers are now leaning toward quicker, more inclusive methods like MCED, which requires a single blood draw and can check for multiple cancers, making it not just convenient but also more likely to get people screened in the first place. As clinical evidence continues to build and regulatory pathways evolve, these tests are poised to see much wider adoption in the years ahead.
DNA methylation profiling: a breakthrough enhancing test accuracy and adoption
cfDNA methylation profiling is one of the notable innovations making MCED more accurate and practical. Traditional screening methods include hunting for specific mutations; this test looks at how DNA is tagged with chemical markers called methylation which changes depending on the type and location of cancer. Even if there-s only a tiny amount of tumor DNA in the blood, these unique patterns can still be detected and used to trace the cancer-s origin. The test gives better precision, compared to other methods, meaning fewer false alarms and less need for stressful follow-up tests. The preliminary data for this test seems to be promising, due to which physicians are incorporating it in everyday preventive or early diagnosis, but for the entire conversation around cancer care. For instance, in February 2025, GRAIL partnered with Quest Diagnostics to make its Galleri test directly accessible to over 500,000 healthcare providers and 7,400 collection sites across the US through Quest Diagnostics' ordering system
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global multi cancer early detection market is marked by the presence of established and emerging market players such Illumina, Inc.; GRAIL, Inc.; Exact Sciences Corporation; FOUNDATION MEDICINE, INC.; Guardant Health; Freenome Holdings, Inc; Elypta AB; AnchorDx and Burning Rock Biotech Limited among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Metric | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023 - 2024 |
| Forecast Period | 2025 - 2030 |
| 15-20% | |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Type and End-user |
| Regional Scope |
|
| Key Companies Mapped | Illumina, Inc.; GRAIL, Inc.; Exact Sciences Corporation; FOUNDATION MEDICINE, INC.; Guardant Health; Freenome Holdings, Inc; Elypta AB; AnchorDx and Burning Rock Biotech Limited among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Global Multi Cancer Early Detection Market Segmentation
This report by Medi-Tech Insights provides thesize of the global multi cancer early detection market at theregional- and country-level from 2023 to 2030. The report further segments the market based on type and end-user.
Market Size & Forecast (2023-2030), By Type, USD Million
- Liquid Biopsy
- Gene Panel
- LDT & Others
Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic Centers
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rli>
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the multi cancer early detection market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the multi cancer early detection market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
